FDA clears PANDA Phase 3 protocol for Pentixapharm's PentixaFor PET/CT study
The clearance advances late-stage development of the company's imaging agent used to detect disease in PET/CT scans.
Read at The Clinical Trial Vanguard โThe clearance advances late-stage development of the company's imaging agent used to detect disease in PET/CT scans.
Read at The Clinical Trial Vanguard โ